Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Author:

Mato Anthony R.1,Nabhan Chadi2,Barr Paul M.3,Ujjani Chaitra S.4,Hill Brian T.5,Lamanna Nicole6,Skarbnik Alan P.7,Howlett Christina7,Pu Jeffrey J.8,Sehgal Alison R.9,Strelec Lauren E.1,Vandegrift Alexandra1,Fitzpatrick Danielle M.1,Zent Clive S.3,Feldman Tatyana7,Goy Andre7,Claxton David F.8,Bachow Spencer Henick6,Kaur Gurbakhash10,Svoboda Jakub1,Nasta Sunita Dwivedy1,Porter David1,Landsburg Daniel J.1,Schuster Stephen J.1,Cheson Bruce D.4,Kiselev Pavel11,Evens Andrew M.10

Affiliation:

1. Center for Chronic Lymphocytic Leukemia, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;

2. University of Chicago Comprehensive Cancer Center, Chicago, IL;

3. Wilmot Cancer Institute, University of Rochester, Rochester, NY;

4. Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC;

5. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;

6. Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;

7. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;

8. Penn State Cancer Institute, Penn State University, Hershey, PA;

9. University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA;

10. Tufts University Medical Center, Boston, MA; and

11. Celgene Corporation, Summit, NJ

Abstract

Key Points Toxicity was the most common reason for discontinuation of ibrutinib or idelalisib in treated patients with CLL. KI-intolerant patients, but less so those with CLL progression, can be successfully treated with an alternate KI.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference26 articles.

1. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.;Burger;N Engl J Med,2015

2. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.;Furman;N Engl J Med,2014

3. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.;Byrd;N Engl J Med,2014

4. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial [abstract].;O’Brien;Blood,2014

5. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.;Byrd;J Clin Oncol,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3